Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2024 13:14 ET | Source: KUEHN LAW, PLLC

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ:...
September 16, 2024 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...
January 02, 2024 16:49 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
November 09, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen

Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th,...
September 06, 2023 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
September 01, 2023 16:37 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
December 15, 2022 10:15 ET | Source: Moore Kuehn

Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....
September 22, 2022 10:35 ET | Source: Moore Kuehn

Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals,...
August 30, 2022 10:06 ET | Source: Moore Kuehn

Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc....